Inventiva S.A. American Depository Shares (IVA) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Inventiva S.A. American Depository Shares (NASDAQ: IVA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $3.83 (+4.93% 1D, market cap $862.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IVA ranks #305 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IVA carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PHAR (Pharming Group N.V. ADS each representing 10) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $863.7M) and ALMS (Alumis Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $871.1M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).
For Inventiva S.A. American Depository Shares (IVA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #305 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0.6% FCF Margin ($24.1M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
While IVA currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.78) and Max Pain ($4.02) forces dealer call-delta covering toward $7.65.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Inventiva S.A. American Depository Shares (IVA) surged +4.93% to $3.83, trading at 23% of its 52-week range ($2.82 – $7.29). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Is IVA a good stock to buy? We came across a bullish thesis on Inventiva S.A. on BioEquity Watch’s Substack. Since the thesis was published on July 31st, IVA shares have pulled back as investors weigh the upcoming Phase
Inventiva's substantial MASH market opportunity hinges on clinical differentiation and adoption among currently untreated patients. Read more on IVA stock here.
Inventiva, Larimar Therapeutics, and Ascentage Pharma face key drug-development milestones, with analysts assigning Buy ratings and triple-digit upside price targets to all three biotech stocks.
Inventiva (NASDAQ:IVA) presents a high-stakes clinical binary play, anchored by a cash runway that extends only into Q2 2027 against a €69.5 million first-half net loss. With no commercial products generating revenue, it
Inventiva (NASDAQ:IVA) said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic dysfunction-associated steatohepat
Lanifibranor Phase III results expected Q4 2026, potential FDA submission H1 2027.
Yahoo Finance coverage on IVA stock catalysts, institutional flow, and earnings outlook.
Inventiva (NASDAQ:IVA) said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth quarter of 2026, afte
Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetesPreclinical data further characterize lanifibranor’s b
Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September investor conference p
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IVA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IVA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Inventiva S.A. American Depository Shares (IVA) ranks #305 by composite RQD confidence (47/100, grade D) and #378 by equity capitalization ($862.4M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while CYRX leads on capital efficiency and profitability with -11.5% ROIC and 47.1% gross margin. PHAR currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with IVA at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IVA
ACTIVE
Inventiva S.A. American Depository Shares | D | 47/100 | — | — | — | +4.93% | $862.4M | Benchmark Subject |
| PHAR Pharming Group N.V. ADS each representing 10 | D+ | 52/100 | — | — | — | +4.09% | $863.7M | /phar-vs-iva → |
| ALMS Alumis Inc. | E | 18/100 | — | — | -35.0% | -5.20% | $871.1M | /alms-vs-iva → |
| CYRX CryoPort Inc. | D- | 39/100 | 11.8x | 47.1% | -11.5% | -6.13% | $875.7M | /cyrx-vs-iva → |
| CRVS Corvus Pharmaceuticals Inc. | E | 27/100 | — | — | -35.0% | -3.29% | $843.7M | /crvs-vs-iva → |
Inventiva S.A. American Depository Shares (IVA) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $862.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-03, Inventiva S.A. American Depository Shares (NASDAQ: IVA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $3.83 (+4.93% 1D, market cap $862.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IVA ranks #305 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IVA carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PHAR (Pharming Group N.V. ADS each representing 10) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $863.7M) and ALMS (Alumis Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $871.1M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).
For Inventiva S.A. American Depository Shares (IVA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #305 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
IVA last traded at $3.83 (+4.93% on volume of 3,248,998 shares), positioning the stock +1.32% above its 50-day simple moving average ($3.78) and -21.19% below its 200-day simple moving average ($4.86). Across its 52-week range of $2.82 to $7.29, IVA sits at the 22.6% percentile with a 14-day RSI of 53.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.35 to $4.31).
IVA carries an RQD Score of 49 out of 100, a letter grade of D, and the verdict label "Roarable Sell — Underperform / Distribution Warning." Across the five pillars, the Fundamental Cash Engine scores 12 out of 20 (ROIC 0%; FCF yield 0%), indicating that the source data shows no return on invested capital and no free cash flow yield. Whale 13F Flow scores 7 out of 20 for institutional accumulation and options positioning. Insider Conviction scores 9 out of 20 based on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 8 out of 20, with a beta of 1.0 and sector sensitivity. Forensic Balance Sheet scores 13 out of 20, supported by an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.
For a prospective investor evaluating the stock today, the rating points to weak cash-generation evidence and a negative verdict, with the balance-sheet pillar being the relatively stronger component. Upside drivers cannot be assessed from the cash-engine pillar given its 0% readings. The verdict label itself signals distribution risk per the RQD framework.
.A. American Depository Shares (IVA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The profile identifies the company's market capitalization as $0.9B.
Gross margin, operating margin, and net margin are each reported as 0%, and ROIC is reported as 0%. The forensic balance-sheet readings are an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.
The butterfly supply-chain graph lists no upstream or downstream dependencies and no sector correlations. Second-order bottlenecks cannot be identified from the source data.
Real-time company headlines, analyst actions, and sector developments for Inventiva S.A. American Depository Shares (IVA) • Click "Debate This Headline" to argue it in the Roar Pit below
Is IVA a good stock to buy? We came across a bullish thesis on Inventiva S.A. on BioEquity Watch’s Substack. Since the thesis was published on July 31st, IVA shares have pulled back as investors weigh the upcoming Phase
Inventiva's substantial MASH market opportunity hinges on clinical differentiation and adoption among currently untreated patients. Read more on IVA stock here.
Inventiva, Larimar Therapeutics, and Ascentage Pharma face key drug-development milestones, with analysts assigning Buy ratings and triple-digit upside price targets to all three biotech stocks.
Inventiva (NASDAQ:IVA) presents a high-stakes clinical binary play, anchored by a cash runway that extends only into Q2 2027 against a €69.5 million first-half net loss. With no commercial products generating revenue, it
Inventiva (NASDAQ:IVA) said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic dysfunction-associated steatohepat
Lanifibranor Phase III results expected Q4 2026, potential FDA submission H1 2027.
Yahoo Finance coverage on IVA stock catalysts, institutional flow, and earnings outlook.
Inventiva (NASDAQ:IVA) said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth quarter of 2026, afte
Don't sleep on IVA's setup in Health Care. The forensic balance sheet pillar scores 13 out of 20, supported by an Altman Z of 2.5 and a Piotroski F of 6/9.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (47/100) backs up the fundamental quality.
@AlphaFlow_Cap Agree on the RQD 47/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.65 and keeping dry powder in case we test $3.39.
Here is the bear case nobody on the bull side wants to address on IVA: The fundamental cash engine shows ROIC of 0% and FCF yield of 0%, and the overall verdict is Underperform / Distribution Warning.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).